RCT | Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment. 7 Dec, 2022 | 14:29h | UTC Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) – The Lancet
Open access
Open access